Loading…
Loading…
Halozyme Therapeutics, Inc. (HALO) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Four GARP stocks combine discounted PEG ratios with strong growth prospects, offering investors value and potential in 2026.
SAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced that Dr. Helen Torley, President and Chief Executive Officer, and Darren Snellgrove, Chief Financial Officer, are scheduled to participate and host investor meetings at the following investor conferences.
Halozyme Therapeutics is evolving into a diversified, high-margin royalty platform, reducing reliance on single assets like DARZALEX SC. HALO delivered 48% YoY revenue growth in 2Q26, with royalty revenue up 50% and EBITDA margins reaching 68%; full-year guidance was raised across all key metrics. Royalty streams are broadening across mature and new products, with sequential growth from recent launches and a robust pipeline targeting launches from 2029 onward.
Halozyme Therapeutics (HALO) possesses solid growth attributes, which could help it handily outperform the market.
Canada Pension Plan Investment Board acquired a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ: HALO) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 132,600 shares of the biopharmaceutical company's stock, valued at approximately $10,379,000. Canada Pension Plan Investment
Freestone Grove Partners LP bought a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ: HALO) during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 18,192 shares of the biopharmaceutical company's stock, valued at approximately $1,424,000. A
Does Halozyme Therapeutics (HALO) have what it takes to be a top stock pick for momentum investors? Let's find out.